Physician profile
Dana Pan
NPI 1265842934
$11,330.04
in general payments reported to CMS, 2019-2025
27 companies · $3,579 in 2025
The $3,579 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $614 · 2021: $1,436 · 2022: $1,563 · 2023: $2,164 · 2024: $1,974 · 2025: $3,579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,063 · Travel and Lodging: $1,280 · Education: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,062.65 |
| Travel and Lodging | $1,279.83 |
| Education | $374.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,914.18 | 2020-2025 | |
| Boston Scientific Corporation | $1,652.19 | 2025 | Overstitch Endoscopic Suturing System |
| Janssen Biotech, INC. | $981.93 | 2020-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $872.92 | 2020-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $599.08 | 2020-2025 | Entyvio |
| Ironwood Pharmaceuticals, INC | $507.09 | 2020-2024 | Linzess |
| Gilead Sciences, INC. | $491.60 | 2020-2025 | Vemlidy |
| Celgene Corporation | $459.92 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $425.52 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $414.33 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $259.19 | 2020-2023 | Ocaliva |
| Redhill Biopharma INC. | $236.78 | 2021-2023 | Talicia |
| E.R. Squibb & Sons, L.L.C. | $235.55 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $211.23 | 2020-2024 | Dificid |
| Qol Medical, LLC | $190.20 | 2021-2025 | Sucraid, Sucraid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $126.24 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $125.71 | 2023 | |
| Olympus America INC. | $124.99 | 2020 | |
| Pfizer INC. | $121.58 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $100.61 | 2023 | Dupixent |
| Madrigal Pharmaceuticals | $88.81 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $77.44 | 2024-2025 | Rebyota |
| Vivus LLC | $38.17 | 2022-2025 | Pancreaze |
| Nestle Healthcare Nutrition INC. | $24.97 | 2021 | |
| Evoke Pharma, INC. | $19.96 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $16.65 | 2025 | Iqirvo |
| Erbe USA INC | $13.20 | 2023 | Erbe Vio3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Pan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.